Pay in 4 interest-free payments of $6.02 Learn more
Ships within 48 hours · Estimated delivery Sep 22 - Sep 27
Tirzepatide is a dual agonist that targets glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1)
As I wrote about here, their ads trivialize the use of GLP-1s and cross a line into irresponsible promotion
Stay hydrated and eat in smaller portions to prevent nausea and constipation
Tan S, Chen S
The future of GLP-1 drug delivery is not just about efficacy it is about responsibility
Building on these research findings, Eli Lilly developed a dual agonist targeting GLP-1R/GIPR, called tirzepatide, which was approved by the FDA in 2022 and showed promising therapeutic effects for T2D and obesity
US$ 26.16
US$ 20.87
US$ 24.41
US$ 26.10
US$ 28.01
US$ 26.26
US$ 28.84
US$ 24.71
US$ 25.52
